RxDoctor Payments Data

Neelum Gupta, MD

Internal Medicine · Berkley, MINPI 1811901309

Payments from drug & device makers

$7,166in general payments, 2019–2025

Across 362 payments — averaging $19.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Pfizer$864
  • Amgen$796
  • Novo Nordisk$685
  • GSK$481
  • Boehringer Ingelheim$324
  • plus $3K from 41 others

What the payments were for

  • Food & beverage$7,159100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,166 in reported general payments places this provider in the 90th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$253,150
Medicare patients
260
Services billed
4,432

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban47$43,058
JardianceEmpagliflozin27$30,906
OzempicSemaglutide22$27,614
FarxigaDapagliflozin Propanediol30$26,982
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$21,927
MounjaroTirzepatide13$15,104
JanuviaSitagliptin Phosphate15$12,661
Breo ElliptaFluticasone/Vilanterol11$4,185
Atorvastatin Calcium328$3,749
Metoprolol Succinate138$2,554
Losartan Potassium137$1,539
Alendronate Sodium49$1,390
Rosuvastatin Calcium95$1,269
Amlodipine Besylate201$1,221
Levothyroxine Sodium84$1,056

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$864$43,05847 claims
Boehringer IngelheimJardiance$324$30,90627 claims
Novo NordiskOzempic$685$27,61422 claims
AstraZenecaFarxiga$1,372$26,98230 claims
GSKTrelegy Ellipta, Breo Ellipta$481$26,11243 claims
Lilly USA, LLCMounjaro$298$15,10413 claims
MerckJanuvia$75$12,66115 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$50$1,05684 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Berkley

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →